Mark Coleman, Director at Axsome Therapeutics, Inc. (AXSM), bought 2,063 shares at $127.40 ($263K) on 2025-09-08, disclosed to the SEC on 2025-09-09.
Open-market purchase of $263k AXSM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $127.20 | 800 | $102K | 38.7% |
| 2 | $127.30 | 287 | $37K | 13.9% |
| 3 | $127.40 | 488 | $62K | 23.7% |
| 4 | $127.40 | 488 | $62K | 23.7% |
| Total | $127.31 avg | 2,063 | $263K | 100% |
| Filing → |
| AXSM | SELL | 2026-02-27 | $4.0M | — | Filing → |
| AXSM | SELL | 2025-05-29 | $1.6M | — | Filing → |
| AXSM | SELL | 2025-05-20 | $322K | — | Filing → |